Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07671833 · ClinicalTrials.gov registry record · Phase 1
A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07671833 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 24 participants.
The verdict
NCT07671833, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.
Interventions
- DRUG LY03015 (LPM3770164 extended-release tablets)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2026-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07671833
The ClinicalTrials.gov registry entry for NCT07671833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY03015 (LPM3770164 extended-release tablets) is the first listed.
NCT07671833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07671833 about?
NCT07671833 is a clinical study titled "A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects". This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening ...
What is the current status of trial NCT07671833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-04-15. Estimated completion is 2026-05-27.
What interventions are being tested in trial NCT07671833?
The interventions under investigation include: LY03015 (LPM3770164 extended-release tablets) (DRUG).
Who is sponsoring clinical trial NCT07671833?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.